Inactive Instrument

Baytacare Pharmaceutical Co., Ltd.

8197

CNE100000155

Baytacare Pharmaceutical Co., Ltd. Announces Changes in Address, Effective from June 1, 2018

June 01, 2018 at 05:39 am EDT

The board of directors of Baytacare Pharmaceutical Co.,Ltd. announced that the principal place of business of the company in Hong Kong has been changed to 12th Floor, Kam Sang Building, 255-257 Des Voeux Road Central, Hong Kong with effect from 1 June 2018.

Latest news about Baytacare Pharmaceutical Co., Ltd.

Baytacare Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-13	CI
Baytacare Pharmaceutical Co., Ltd. Announces the Resignation of Shi Peng as a Non-Executive Director	19-10-23	CI
Baytacare Pharmaceutical Co., Limited Announces Resignation of Lam Kai Yeung as the Company Secretary	19-09-17	CI
Baytacare Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-12	CI
Baytacare Pharmaceutical Co., Ltd. Establishes an Independent Board Committee of Board of Directors	19-08-02	CI
Baytacare Pharmaceutical Co., Ltd. Announces Change of Directors and Change of Composition of Board Committees	19-07-01	CI
Baytacare Pharmaceutical Co., Ltd. Announces Change of Registered Address	19-07-01	CI
Baytacare Pharmaceutical Co., Ltd. completed the acquistion of 70% stake in Hubei Taofuan Electronics Commerce Co., Ltd. from Taofuan Holdings Co., Ltd.	19-06-20	CI
Baytacare Pharmaceutical Co., Ltd. Announces Change of Company Secretary	19-06-10	CI
Baytacare Pharmaceutical Co., Ltd. entered into an agreement to acquire 70% stake in Hubei Taofuan Electronics Commerce Co., Ltd. from Taofuan Holdings Co., Ltd. for CNY 1.5 million.	19-05-30	CI
Baytacare Pharmaceutical Co., Ltd. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019	19-05-15	CI
Baytacare Pharmaceutical Co., Ltd. Reports Consolidated Earnings Results for the Year Ended December 31, 2018	19-04-29	CI
Baytacare Pharmaceutical Co., Ltd. Appoints Zhu Tianxiang as Independent Non-Executive Director, Chairman of the Remuneration Committee, Member of the Audit Committee and Member of the Nomination Committee	19-04-24	CI
Baytacare Pharmaceutical Co., Ltd. Provides Loss Guidance for the Year Ended December 31, 2018	19-04-15	CI
Baytacare Pharmaceutical Co., Ltd. Announces Board Changes	19-04-15	CI
General Beidou Information Technology Co., Ltd. cancelled the acquisition of Anhui Baytacare Health Data Co., Ltd. from Baytacare Pharmaceutical Co., Ltd..	18-12-21	CI
Baytacare Pharmaceutical Co., Ltd. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	18-11-15	CI
Baytacare Pharmaceutical Co., Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	18-08-10	CI
Baytacare Pharmaceutical Co., Ltd. Announces Executive Changes	18-07-09	CI
Baytacare Pharmaceutical Co., Ltd. Announces Board and Committee Changes	18-06-18	CI
Baytacare Pharmaceutical Co., Ltd. Enters into a Strategic Framework Agreement with Zhuhai Guangyuan Co., Ltd	18-06-08	CI
Baytacare Pharmaceutical Co., Ltd. Announces Changes in Address, Effective from June 1, 2018	18-06-01	CI
Baytacare Pharmaceutical Co., Ltd. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2018	18-05-14	CI
Baytacare Pharmaceutical Co., Ltd. Announces Management Changes	18-04-26	CI
Baytacare Pharmaceutical Co., Ltd. Announces Resignation of Yang Yulinas as an Independent Non-Executive Director	18-04-03	CI

Chart Baytacare Pharmaceutical Co., Ltd.

Duration

Period

Chart Baytacare Pharmaceutical Co., Ltd.

More charts

Company Profile

Baytacare Pharmaceutical Co., Ltd., formerly Northeast Tiger Pharmaceutical Co., Ltd., is principally engaged in the sales of pharmaceutical products. The Company mainly operates through two business segments. The Medicines Business segment is engaged in the development, manufacture and sales of medicines. The Chinese Herbs Business segment is engaged in the planting, cultivation and sales of Chinese herbs. The Company mainly conducts its businesses in Mainland China. The Company is also engaged in the investment holding business through its subsidiaries in the People's Republic of China (the PRC). Its principal subsidiary includes Antao County Northeast Tiger Xinxing New Products Co., Limited.

Sector

Pharmaceuticals

More about the company

Sector Alternative Medicine

	1st Jan change	Capi.
DONG-E-E-JIAO CO.,LTD.	+42.38%	6.26B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.86%	4.49B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+6.36%	3.29B
TASLY PHARMACEUTICAL GROUP CO., LTD	-11.28%	3.12B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-3.23%	2.5B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+45.24%	1.94B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-0.98%	1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-11.32%	1.56B

Alternative Medicine